Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F WIELAND

Showing results (251-260 of 269) with videos related to

Pageof 27
Sort By:
BJU International|January 12, 2013
Ki-67, mini-chromosome maintenance 2 protein (MCM2) and geminin have no independent prognostic relevance for cancer-specific survival in surgically treated squamous cell carcinoma of the penisMatthias May, Maximilian Burger, Wolfgang Otto, et al.
The Journal of Infectious Diseases|May 29, 2024
Nasal and Pharyngeal Mucosal Immunity to Poliovirus in Children Following Routine Immunization With Inactivated Polio Vaccine in the United StatesAudrey Godin, Ruth I Connor, Hanna N Degefu, et al.
The Journal of Urology|February 17, 2012
External validation of a risk model to predict recurrence-free survival after radical cystectomy in patients with pathological tumor stage T3N0 urothelial carcinoma of the bladderMatthias May, Patrick J Bastian, Sabine Brookman-May, et al.
European Urology|October 20, 2012
Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph node-positive urothelial carcinomaHans-Martin Fritsche, Matthias May, Stefan Denzinger, et al.
Scandinavian Journal of Urology and Nephrology|March 11, 2011
Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladderMatthias May, Patrick J Bastian, Sabine Brookman-May, et al.
Der Urologe. Ausg. A|October 6, 2010
[Patients with bladder cancer in clinical stage T2 : survival benefit of downstaging in comparison to patients with confirmed muscle invasion in cystectomy specimens]M May, H-M Fritsche, S Brookman-May, et al.
Annals of Surgical Oncology|January 20, 2011
Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomyMatthias May, Edwin Herrmann, Christian Bolenz, et al.
Urologic Oncology|November 8, 2011
Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4aMatthias May, Patrick J Bastian, Sabine Brookman-May, et al.
European Urology|February 8, 2011
Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomyMatthias May, Edwin Herrmann, Christian Bolenz, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 31, 2012
External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladderP Nuhn, M May, H-M Fritsche, et al.
Pageof 27

Showing results (251-260 of 269) with videos related to

Sort By:
Pageof 27
BJU International|January 12, 2013
Ki-67, mini-chromosome maintenance 2 protein (MCM2) and geminin have no independent prognostic relevance for cancer-specific survival in surgically treated squamous cell carcinoma of the penisMatthias May, Maximilian Burger, Wolfgang Otto, et al.
The Journal of Infectious Diseases|May 29, 2024
Nasal and Pharyngeal Mucosal Immunity to Poliovirus in Children Following Routine Immunization With Inactivated Polio Vaccine in the United StatesAudrey Godin, Ruth I Connor, Hanna N Degefu, et al.
The Journal of Urology|February 17, 2012
External validation of a risk model to predict recurrence-free survival after radical cystectomy in patients with pathological tumor stage T3N0 urothelial carcinoma of the bladderMatthias May, Patrick J Bastian, Sabine Brookman-May, et al.
European Urology|October 20, 2012
Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph node-positive urothelial carcinomaHans-Martin Fritsche, Matthias May, Stefan Denzinger, et al.
Scandinavian Journal of Urology and Nephrology|March 11, 2011
Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladderMatthias May, Patrick J Bastian, Sabine Brookman-May, et al.
Der Urologe. Ausg. A|October 6, 2010
[Patients with bladder cancer in clinical stage T2 : survival benefit of downstaging in comparison to patients with confirmed muscle invasion in cystectomy specimens]M May, H-M Fritsche, S Brookman-May, et al.
Annals of Surgical Oncology|January 20, 2011
Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomyMatthias May, Edwin Herrmann, Christian Bolenz, et al.
Urologic Oncology|November 8, 2011
Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4aMatthias May, Patrick J Bastian, Sabine Brookman-May, et al.
European Urology|February 8, 2011
Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomyMatthias May, Edwin Herrmann, Christian Bolenz, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 31, 2012
External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladderP Nuhn, M May, H-M Fritsche, et al.
Pageof 27